PPAR-gamma inhibitors as novel tubulin-targeting agents.
The microtubule-targeting agents are one of the most successful classes of cancer therapeutics. All known antimicrotubule drugs bind to microtubules, or to their constituent tubulin heterodimers, and affect microtubule polymerization and dynamics. Recently, PPAR-gamma inhibitors were shown to reduce tubulin levels without affecting the polymerization of tubulin in vitro. This observation suggests the possible development of antimicrotubule drugs that target tubulin itself, rather than the equilibrium between tubulin and microtubules.
Schaefer
Katherine L
KL
D017209:Apoptosis / Q000187:drug effects; D045744:Cell Line, Tumor; D002465:Cell Movement / Q000187:drug effects; D006801:Humans; D008870:Microtubules / Q000187:drug effects / Q000378:metabolism; D009369:Neoplasms / Q000188:drug therapy; D047495:PPAR gamma / Q000037:antagonists & inhibitors* / Q000494:pharmacology*; D012680:Sensitivity and Specificity; D014404:Tubulin / Q000187:drug effects* / Q000378:metabolism; D050257:Tubulin Modulators / Q000494:pharmacology*
D047495:PPAR gamma; D014404:Tubulin; D050257:Tubulin Modulators